Drug intelligence / Profile preview

BB2603-3

Development stage: Unknown
Lead developer: Blueberry Therapeutics
Modality: Small Molecules
Administration: Topical

Overview

BB2603-3 is a topical antifungal nano-formulation containing 0.03% terbinafine and 0.09% polyhexanide (PHMB). It is delivered as a spray for the treatment of fungal infections of the nail (onychomycosis) and skin (tinea pedis). The formulation uses nanotechnology to enhance drug delivery through the nail and into the skin, allowing for lower doses while maintaining efficacy and minimizing systemic side effects.

Targets

SQLE (Squalene monooxygenase)

Beyond the preview

Go deeper on BB2603-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BB2603-3.

Explore the full profile